• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 1, 2020
Distillery Therapeutics

Blocking necroptosis to treat inflammatory bowel disease

Read More
BioCentury | Jul 10, 2019
Distillery Therapeutics

Activating RIPK3 could help treat melanoma and lung cancer

Read More
BioCentury | Aug 31, 2017
Targets & Mechanisms

Necroptosis strikes again

Direct evidence of necroptosis in Alzheimer's
Read More
BioCentury | May 12, 2016
Distillery Therapeutics

Therapeutics: Receptor-interacting serine-threonine kinase 3 (RIPK3; RIP3); tumor necrosis factor receptor 1 (TNFRSF1A; TNFR1; CD120a); HECT domain and ankyrin

Read More
BioCentury | Apr 28, 2016
Distillery Therapeutics

Therapeutics: Fas-associated via death domain (FADD); receptor-interacting serine-threonine kinase 3 (RIPK3; RIP3)

Read More
BioCentury | Apr 14, 2016
Distillery Therapeutics

Therapeutics: Receptor-interacting serine-threonine kinase 3 (RIPK3; RIP3)

Read More
BioCentury | Mar 3, 2016
Distillery Therapeutics

Therapeutics: Receptor-interacting serine-threonine kinase 3 (RIPK3; RIP3); mixed-lineage kinase domain-like (MLKL)

Read More
BioCentury | Jan 21, 2016
Distillery Therapeutics

Therapeutics: Receptor-interacting serine-threonine kinase 3 (RIPK3; RIP3); calcium calmodulin-dependent protein kinase II (CAMK2)

Read More
BioCentury | Feb 13, 2014
Targets & Mechanisms

A RIPping target in Gaucher's disease

Read More
BioCentury | Feb 6, 2014
Distillery Therapeutics

Indication: Endocrine/metabolic disease

Read More
Items per page:
1 - 10 of 12